Efficacy and safety of remifentanil for analgesia in cesarean delivery

Medicine (Baltimore). 2017 Dec;96(48):e8341. doi: 10.1097/MD.0000000000008341.

Abstract

Background: This study aimed to assess the efficacy and safety of remifentanil as a general anesthetic during cesarean delivery.

Material and methods: Fifty women with singleton pregnancies undergoing cesarean delivery were randomly divided into intervention and control groups, each group containing 25 subjects. Participants in the intervention group received remifentanil (infused at 2 μg/kg/h), whereas subjects in the control group were given dexmedetomidine (infused at 0.4 μg/kg/h). Outcome measurements included mean arterial blood pressure (MAP), heart rate (HR), bispectral index (BIS), Apgar scores at 1 and 5 minutes, and the pH, PCO2, PO2, and base excess (BE) of umbilical venous and arterial blood.

Results: Forty-four participants completed the study. Patients in the intervention group did not experience greater effect and safety than those in the control group (P > .05), although MAP and BIS values decreased significantly immediately before laryngoscopy (P < .05). In addition, BIS values were reduced significantly at the time of skin incision, at uterine incision, and immediately after fetal delivery when compared with baseline values in both groups (P < .01).

Conclusion: This study concluded that remifentanil and dexmedetomidine exhibited similar efficacy and safety during general anesthesia for cesarean delivery.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Analgesics, Non-Narcotic / therapeutic use
  • Analgesics, Opioid / therapeutic use*
  • Cesarean Section*
  • Dexmedetomidine / therapeutic use
  • Female
  • Humans
  • Patient Safety
  • Piperidines / therapeutic use*
  • Pregnancy
  • Remifentanil
  • Treatment Outcome

Substances

  • Analgesics, Non-Narcotic
  • Analgesics, Opioid
  • Piperidines
  • Dexmedetomidine
  • Remifentanil